WSW, NY, March 18th, 2026, FinanceWire
PolyPid’s Phase 3-validated D-PLEX100 is expected to start its rolling NDA submission within weeks, as Medicare’s new TEAM model increases the financial urgency for hospitals to prevent costly surgical infections.
PolyPid (NASDAQ: PYPD) is now less than two weeks away from initiating its NDA submission for D-PLEX100, after receiving a $4.3 million PDUFA fee waiver from the FDA – removing a key financial hurdle ahead of what could be a pivotal regulatory milestone. The company’s Phase 3-validated drug candidate is designed to prevent surgical site infections (SSIs) in colorectal procedures, one of the most costly complications hospitals face. At the same time, a major shift in how Medicare reimburses surgical care is increasing the financial urgency for hospitals to prevent these infections. Under the new Transforming Episode Accountability Model (TEAM), hospitals are financially responsible for complications for 30 days post-surgery – including colorectal procedures where SSIs are among the most frequent and costly outcomes – aligning policy pressure with the problem D-PLEX100 is designed to address.
Hospitals already face penalties for high infection rates under CMS’s Hospital-Acquired Condition Reduction Program, and TEAM adds another layer of financial exposure. For colorectal procedures, SSI prevention is no longer just a quality initiative; it is a reimbursement imperative, and PolyPid appears to be developing the only late-stage product specifically designed to address it.
A Product Built for a 30-Day Problem
PolyPid’s lead product candidate, D-PLEX100, provides local, prolonged antibiotic protection directly at the surgical site. Administered during surgery, the product uses PolyPid’s proprietary Kynatrix technology, built on its PLEX (Polymer-Lipid Encapsulation matriX) drug delivery system, to deliver a continuous, controlled release of the broad-spectrum antibiotic doxycycline for 30 days. That duration is not incidental. It matches precisely the 30-day post-discharge accountability window that TEAM now imposes on hospitals.
In the pivotal Phase 3 SHIELD II trial, a prospective, randomized, double-blind study of 798 patients undergoing abdominal colorectal surgery with large incisions, D-PLEX100 met its composite primary endpoint, showing a 40% reduction in SSIs, surgical reinterventions, and mortality combined (p<0.005) when added to standard of care. In a key secondary analysis, the product demonstrated a 60% reduction in SSI rates specifically (p<0.005). Conventional SSI prevention relies on systemic antibiotics that clear the body within hours, long before most infections develop. D-PLEX100 addresses this gap by maintaining high local antibiotic concentrations at the wound site for weeks, using only a fraction of the doxycycline dose that systemic delivery would require.
Why TEAM Changes the Calculus for Hospitals
Before TEAM, a colorectal SSI was a clinical problem that, according to a study published in Diseases of the Colon & Rectum, could add anywhere from roughly $18,000 to over $100,000 in costs for Medicare patients depending on infection severity. But the financial consequences were dispersed across payers and absorbed through the fee-for-service system, which paid for each additional service rendered. Hospitals were, in effect, compensated for treating the complication.
TEAM reverses that dynamic. Hospitals receive a target price for each surgical episode, and every complication within the 30-day window counts against it. In 2026, risk is limited to upside only, but starting in 2027, up to 20% of a hospital’s target reimbursement is at risk. For a hospital performing hundreds of colorectal surgeries per year, even a modest reduction in SSI rates could translate to meaningful savings.
The combination of the HAC Reduction Program’s existing penalties and TEAM’s new episode-based accountability creates a dual financial incentive for hospitals to invest in SSI prevention. For a product like D-PLEX100, this policy environment could accelerate hospital adoption when the product reaches market.
Regulatory Momentum and Commercial Preparations
D-PLEX100 holds Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations from the FDA, the latter of which provides five years of market exclusivity upon approval in addition to the three years of exclusivity the product is eligible for through the 505(b)(2) approval pathway. In December 2025, PolyPid received positive pre-New Drug Application (NDA) meeting minutes from the FDA confirming that the company’s clinical data package appears adequate to support NDA submission and review. The FDA also agreed to a rolling NDA, allowing PolyPid to submit completed sections ahead of the full filing. The company has since confirmed it remains on track to initiate the rolling NDA submission by the end of March 2026, placing the start of the regulatory process within weeks.
On its Q4 2025 earnings call in February 2026, management guided that the rolling NDA is expected to begin by the end of Q1 2026, with manufacturing and technical data filed first and clinical data following shortly after. With the Breakthrough Therapy and Fast Track designations, the company anticipates a priority review of approximately six months, which could pull forward an approval decision relative to the standard timeline.
On the commercial front, PolyPid (NASDAQ:PYPD) has disclosed that it is in advanced stages of U.S. partnership discussions for D-PLEX100, with potential partners described as hospital-focused organizations with deep operating room presence. A partnership of this type could be significant for a company of PolyPid’s size, potentially providing the commercial infrastructure needed to reach surgical teams at hospitals navigating TEAM’s financial requirements. Beyond D-PLEX100, PolyPid’s Kynatrix technology underpins a broader pipeline spanning oncology and metabolic diseases, including a ultra long-acting GLP-1 receptor agonist program in preclinical development.
Conclusion
The CMS TEAM model has created a new financial reality for hospitals performing colorectal surgery. SSI prevention is now directly tied to how hospitals are reimbursed for the full episode of care. PolyPid’s D-PLEX100, with Phase 3 data showing a 60% reduction in SSIs over the exact 30-day window that defines hospital accountability, appears positioned at the intersection of clinical need and policy-driven demand. The rolling NDA submission is expected to begin imminently, partnership discussions are advancing, and regulatory designations suggest an accelerated path. For investors watching surgical care economics, this convergence of policy incentive and clinical data may represent a setup worth following closely.
Read this next >>
Recent News Highlights from PolyPid:
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from PolyPid Ltd for coverage and awareness services provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. Full compensation details updated in retail time, alongside information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures and we encourage readers to review them in full. This article should not be considered an official communication of the issuer.